Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline

Pediatr Blood Cancer. 2022 Dec;69(12):e30001. doi: 10.1002/pbc.30001. Epub 2022 Oct 11.


This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.

Keywords: chemotherapy-induced nausea and vomiting; guideline; pediatric oncology; supportive care.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiemetics* / therapeutic use
  • Antineoplastic Agents* / adverse effects
  • Child
  • Humans
  • Nausea / chemically induced
  • Nausea / drug therapy
  • Nausea / prevention & control
  • Neoplasms* / drug therapy
  • Randomized Controlled Trials as Topic
  • Systematic Reviews as Topic
  • Vomiting / chemically induced
  • Vomiting / drug therapy
  • Vomiting / prevention & control


  • Antiemetics
  • Antineoplastic Agents